Delstrigo 300 mg

DELSTRIGO 300 MG tablets contain lamivudine, an antiviral medication used to manage HIV infections. This oral treatment is manufactured by Merck Canada Inc. and is available in a 30-tablet pack.

DELSTRIGO 300 MG tablets are primarily used in the treatment of HIV infections. Lamivudine, the active ingredient, works by inhibiting the replication of the HIV virus. This medication is often part of a combination therapy to manage HIV and improve immune function. Patients should consult their healthcare provider to determine if DELSTRIGO 300 MG is suitable for their specific condition.

Common effects of DELSTRIGO 300 MG tablets may include headaches, nausea, and fatigue. Some users might experience dizziness or insomnia. These effects vary among individuals and are not experienced by everyone. If any effects persist or worsen, it is advisable to seek medical advice.

DELSTRIGO 300 MG tablets should be stored at room temperature, away from moisture and heat. It is important to follow the prescribed dosage and administration instructions provided by a healthcare professional. Patients with known allergies to lamivudine or any of the inactive ingredients should avoid this medication. Pregnant or breastfeeding women should consult their healthcare provider before use.

DELSTRIGO 300 MG tablets may interact with other medications, including certain antiviral drugs and immune modulators. Alcohol consumption should be avoided as it may exacerbate side effects. Patients taking other medications should inform their healthcare provider to avoid potential interactions. Always consult a healthcare professional before starting any new medication.